Block of the Angiotensin Pathways Affects Flow-Volume Spirometry in Patients with SARS-CoV-2 Infection.
Angiotensin pathway
Flow-volume spirometry
SARS-CoV-2
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
2
11
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
Angiotensin Converting Enzyme 2 (ACE2) is an endothelial cell receptor used by SARS-CoV- 2 virus to enter cells. Pulmonary function tests (PFTs), mainly spirometry, are the main diagnostic tools for most respiratory diseases. PFTs are mandatory for assessing the response to therapy. We evaluated patients after the SARS-CoV-2 infection through flow-volume spirometry that evaluates the role of drugs inhibiting the ACE2 pathway. We evaluated 112 Caucasian patients 3-6 months after COVID-19 disease, i.e. after the date of negative molecular or antigenic nasopharyngeal swab. The series of patients showed a great variability due to a wide spectrum of age, the severity of disease manifestations, hospitalization, invasive/non-invasive ventilation, comorbidities, the presence/absence of a previous pneumological diagnosis and the variants of the virus. Patients were divided into those who were being treated with angiotensin receptor blocker (ARB) or ACE2 inhibitors (ACEi) (ARB/ACEi, group 1, 23 females and 12 males, aged 63.63 ± 10.40), and those who were not treated with these drugs (group 2, 38 females and 37 males, aged 55.12 ± 16.51). Distal airflow obstruction (DAO) was evaluate as forced expiratory flow (FEF) at 25%, 50% and 75% of total flow. Group 1 presented lower peripheral oxygen saturation percentage vs group 2 (96.54 ± 3.06 vs 97.30 ± 1.19%, p < 0.05). Spirometry data were worst in group1: Forced expiratory volume at first minute (FEV1) (91.20 ± 17.09 vs 97.56 ± 16.40%, p < 0.05), Forced vital capacity (94.06 ± 17.48 vs 99.13 ± 17.71%, p < 0.05), and Tiffenau Index (0.78 ± 0.12 vs 0.84 ± 0.10, p < 0.05). There was a DAO in group1. In group 1, we found also a reduction in FEF 25 (73.97 ± 27.28 vs 86.89 ± 22.44%, p < 0.05), FEF 50 (74.69 ± 33.01 vs 85.67 ± 23.74%, p < 0.05), and FEF 25-75 (74.14 ± 35.03 vs 83.92 ± 25.38%, p < 0.05) but not in FEF 75 (73.06 ± 39.37 vs 82.27 ± 43.33%, p < 0.05). In patients treated with ARB/ACEi the indexes of respiratory function were shifted towards the lower limits (albeit within normal limits). These parameters were significantly reduced compared to patients not treated with these drugs. This indicates that the COVID-19 disease is not only a pulmonary disease, but also a vascular one.
Sections du résumé
BACKGROUND
BACKGROUND
Angiotensin Converting Enzyme 2 (ACE2) is an endothelial cell receptor used by SARS-CoV- 2 virus to enter cells. Pulmonary function tests (PFTs), mainly spirometry, are the main diagnostic tools for most respiratory diseases. PFTs are mandatory for assessing the response to therapy.
AIM
OBJECTIVE
We evaluated patients after the SARS-CoV-2 infection through flow-volume spirometry that evaluates the role of drugs inhibiting the ACE2 pathway.
MATERIAL AND METHODS
METHODS
We evaluated 112 Caucasian patients 3-6 months after COVID-19 disease, i.e. after the date of negative molecular or antigenic nasopharyngeal swab. The series of patients showed a great variability due to a wide spectrum of age, the severity of disease manifestations, hospitalization, invasive/non-invasive ventilation, comorbidities, the presence/absence of a previous pneumological diagnosis and the variants of the virus. Patients were divided into those who were being treated with angiotensin receptor blocker (ARB) or ACE2 inhibitors (ACEi) (ARB/ACEi, group 1, 23 females and 12 males, aged 63.63 ± 10.40), and those who were not treated with these drugs (group 2, 38 females and 37 males, aged 55.12 ± 16.51). Distal airflow obstruction (DAO) was evaluate as forced expiratory flow (FEF) at 25%, 50% and 75% of total flow.
RESULTS
RESULTS
Group 1 presented lower peripheral oxygen saturation percentage vs group 2 (96.54 ± 3.06 vs 97.30 ± 1.19%, p < 0.05). Spirometry data were worst in group1: Forced expiratory volume at first minute (FEV1) (91.20 ± 17.09 vs 97.56 ± 16.40%, p < 0.05), Forced vital capacity (94.06 ± 17.48 vs 99.13 ± 17.71%, p < 0.05), and Tiffenau Index (0.78 ± 0.12 vs 0.84 ± 0.10, p < 0.05). There was a DAO in group1. In group 1, we found also a reduction in FEF 25 (73.97 ± 27.28 vs 86.89 ± 22.44%, p < 0.05), FEF 50 (74.69 ± 33.01 vs 85.67 ± 23.74%, p < 0.05), and FEF 25-75 (74.14 ± 35.03 vs 83.92 ± 25.38%, p < 0.05) but not in FEF 75 (73.06 ± 39.37 vs 82.27 ± 43.33%, p < 0.05).
DISCUSSION
CONCLUSIONS
In patients treated with ARB/ACEi the indexes of respiratory function were shifted towards the lower limits (albeit within normal limits). These parameters were significantly reduced compared to patients not treated with these drugs. This indicates that the COVID-19 disease is not only a pulmonary disease, but also a vascular one.
Identifiants
pubmed: 37845465
doi: 10.1007/978-3-031-42003-0_35
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Angiotensins
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-229Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Groß S, Jahn C, Cushman S, Bär C, Thum T (2020) SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications. J Mol Cell Cardiol [Internet] 144(April):47–53. Available from: https://doi.org/10.1016/j.yjmcc.2020.04.031
doi: 10.1016/j.yjmcc.2020.04.031
pubmed: 32360703
Cicco S, Vacca A, Cittadini A, Marra AM (2020) Long-term follow-up may be useful in coronavirus disease 2019 survivors to prevent chronic complications. Infect Chemother [Internet] 52(3):407. Available from: https://doi.org/10.3947/ic.2020.52.e44
doi: 10.3947/ic.2020.52.3.407
pubmed: 32757498
Berlin DA, Gulick RM, Martinez FJ (2020) Severe Covid-19. N Engl J Med 383(25):2451–2460
doi: 10.1056/NEJMcp2009575
pubmed: 32412710
Cicco S, Albanese F, Didonna R, et al (2023) Pulmonary embolism in Covid-19 patients is not related to a deterioration of tissue oxygenation. Adv Exp Med Biol; Oxygen Tra
Klain A, Indolfi C, Dinardo G, Decimo F, Miraglia Del Giudice M (2022) Covid-19 and spirometry in this age. Ital J Pediatr 48(1):4–9
doi: 10.1186/s13052-022-01199-5
Crimi C, Impellizzeri P, Campisi R, Nolasco S, Spanevello A, Crimi N (2021) Practical considerations for spirometry during the COVID-19 outbreak: literature review and insights. Pulmonology [Internet] 27(5):438–447. Available from: https://doi.org/10.1016/j.pulmoe.2020.07.011
doi: 10.1016/j.pulmoe.2020.07.011
pubmed: 32800783
Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuño R (2021) A systematic review of persistent symptoms and residual abnormal functioning following acute covid-19: Ongoing symptomatic phase vs. post-covid-19 syndrome. J Clin Med 10(24):5913
doi: 10.3390/jcm10245913
pubmed: 34945213
pmcid: 8708187
Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X et al (2021) Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology [Internet] 27(4):328–337. Available from: https://doi.org/10.1016/j.pulmoe.2020.10.013
doi: 10.1016/j.pulmoe.2020.10.013
pubmed: 33262076
Jabbar AS, Neamah NF, Al-Darraji AH (2022) Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients. J Basic Clin Physiol Pharmacol 33(2):207–212
doi: 10.1515/jbcpp-2020-0243
Faggiano P, Lombardi C, Sorgato A, Ghizzoni G, Spedini C, Rusconi C (1993) Pulmonary function tests in patients with congestive heart failure: effects of medical therapy. Cardiology 83(1–2):30–35
doi: 10.1159/000175944
pubmed: 8261483
Riska H, Sovijärvi ARA, Ahonen A, Salorinne Y, Sundberg S, Stenius-Aarniala B (1990) Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. J Cardiovasc Pharmacol [Internet] 15(1):57–61. Available from: http://journals.lww.com/00005344-199001000-00009
doi: 10.1097/00005344-199001000-00009
pubmed: 1688983
Mozzini C, Cicco S, Setti A et al (2021) Spotlight on cardiovascular scoring systems in Covid-19: severity correlations in real-world setting. Curr Probl Cardiol [Internet] 46(5):100819. Available from: https://doi.org/10.1016/j.cpcardiol.2021.100819
doi: 10.1016/j.cpcardiol.2021.100819
pubmed: 33631706
Cicco S, Mozzini C, Marozzi M et al (2022) Cardiovascular risk score may be useful in stratify death risk in hospitalized Covid19 patients. J Hypertens [Internet] 40(Suppl 1):e172. Available from: https://journals.lww.com/10.1097/01.hjh.0000837136.87315.11
doi: 10.1097/01.hjh.0000837136.87315.11
Cicco S, Mozzini C, Carella R, et al (2023) Cardiovascular risk score and pulmonary gas exchange in COVID-19 patients show no correlation. Adv Exp Med Biol; Oxygen Tra
Azevedo RB, Botelho BG, de Hollanda JVG et al (2021) Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens [Internet] 35(1):4–11. Available from: https://doi.org/10.1038/s41371-020-0387-4
doi: 10.1038/s41371-020-0387-4
pubmed: 32719447
Xue Y, Sun S, Cai J et al (2020) Effects of ACEI and ARB on COVID-19 patients: a meta-analysis. JRAAS - J Renin-Angiotensin-Aldosterone Syst 21(4):1470320320981321
pubmed: 33325306
Cippà PE, Cugnata F, Ferrari P et al (2020) A data-driven approach to identify risk profiles and protective drugs in COVID-19. Proc Natl Acad Sci U S A 118(1):1–7
Gori M, Ghirardi A, D’Elia E et al (2022) Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19. Eur J Prev Cardiol 29(5):E196–E199
doi: 10.1093/eurjpc/zwab143
pubmed: 34535993